Table 1. Characteristics of the patients at HCC diagnosis (n=26).
| Characteristics | Value |
|---|---|
| Gender | 26 |
| Male | |
| Age | 49 (34–73) |
| Hemophilia type | |
| A | 17 |
| B | 9 |
| Child-Pugh score | 6 (5–11) |
| Child-Pugh grade | |
| A | 17 |
| B | 7 |
| C | 2 |
| HIV treatment | |
| Yes | 20 |
| No | 6 |
| HIV-RNA | |
| Positive | 10 |
| Undetectable | 16 |
| CD4 count | 379 (25–815) |
| HCV treatment | |
| Yes | 11 (3 with DAA) |
| No | 15 |
| HCV-RNA | |
| Positive | 13 |
| Undetectable | 9 |
| Unknown | 4 |
| HCC size (mm) | 21 (7–100) |
| HCC nodule (number) | 1 (1–countless) |
| HCC solitary or multiple | |
| Solitary | 14 |
| Multiple | 12 |
| AFP (ng/mL) | 19.2 (2.7–13,095) |
| PIVKA-II (mAU/mL) | 32.0 (8.0–44.000) |
| HCC primary treatment | |
| Yes | 22 |
| TACE | 13 |
| RFA | 7 |
| TACE + RFA | 1 |
| Resection | 1 |
| No | 4 |
Data are presented as number or median (range). HCC, hepatocellular carcinoma; HIV, human immunodeficiency virus; HCV, hepatitis C virus; DAA, direct acting antivirals; AFP, alfa fetoprotein; PIVKA-II, protein induced by vitamin K absence or antagonist-II; TACE, transcatheter arterial chemoembolization; RFA, radiofrequency ablation.